桑朱养正凉茶通过免疫调节防治呼吸道感染性疾病的多层面机制研究
本研究结合健康人群干预与H1N1 PR8病毒感染小鼠模型,探讨桑朱养正凉茶(SZYZ)防治呼吸道感染性疾病(RTIs)的免疫调节机制。健康人服用后总T细胞、B细胞、CD4+及CD8+ T细胞显著增加,气道微生物多样性下降,Bacteroides与Bifidobacterium富集,机会致病菌减少,血清和粪便代谢物分别有138和197种变化。小鼠模型中SZYZ单用或联用奥司他韦显著降低死亡率和病理损伤,机制涉及氧化应激、炎性细胞因子及淋巴细胞比例调节。
要点
- SZYZ可提升健康人总T细胞、B细胞及CD4+/CD8+ T细胞水平。
- SZYZ调节气道菌群与代谢谱,减少机会致病菌并富集有益菌属。
- SZYZ单用或联用奥司他韦可降低IAV感染小鼠死亡率与病理损伤。
核心结论
- SZYZ通过调节气道微生物群、代谢谱及淋巴细胞亚群发挥免疫调节作用,为RTIs防治提供新思路。
研究设计与样本
- 健康人群干预研究结合H1N1 PR8病毒感染小鼠模型,采用测序与代谢组学技术。
主要发现
- 健康人服用SZYZ后总T细胞、B细胞、CD4+ T细胞及CD8+ T细胞显著增加。
- 16S rRNA测序显示气道微生物多样性下降,Bacteroides与Bifidobacterium富集,Actinobacteria、Synergistetes及Actinomyces、Fretibacterium、Mobiluncus、Cloacibacillus等机会致病菌减少。
- 血清和粪便代谢组学分别鉴定出138和197种代谢物变化。
- 气道Actinobacteria与总T细胞及CD8+ T细胞计数呈负相关;血清甲基十六烷酸水平与T细胞计数负相关、与Actinobacteria丰度正相关。
- IAV感染小鼠中SZYZ预防性给药或联用奥司他韦显著降低死亡率和病理损伤,与氧化应激、炎性细胞因子及淋巴细胞比例免疫调节机制相关。
临床怎么用
- SZYZ可作为RTIs预防和辅助治疗的潜在干预手段,尤其适用于免疫调节需求人群。
- 与奥司他韦联用可能增强抗IAV疗效,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Dysregulation of the upper respiratory tract microbiota, host metabolite profiles, and immune lymphocyte subpopulations is critical in the pathogenesis of respiratory tract infectious diseases (RTIs). Sang Zhu Yang Zheng herbal tea (SZYZ) has emerged as a promising intervention for RTIs, yet its underlying mechanism remains unclear. AIM OF THE STUDY: This study aims to investigate the immunomodulatory mechanisms of SZYZ underlying its role in the prevention and treatment of RTIs. MATERIALS AND METHODS: Human studies were conducted to investigate SZYZ's immunomodulatory effects in preventing RTIs in healthy individuals. In healthy human subjects, SZYZ administration was evaluated for its impact on immune cell counts, airway microbiota composition, and metabolic profiles using advanced sequencing and metabonomic techniques. Murine models were utilized to explore SZYZ's preventive and therapeutic effects, as well as its underlying mechanisms against RTIs, with a focus on influenza A virus (IAV) infection. Murine models were employed with H1N1 PR8 virus infection, and study the therapeutic efficacy and mechanisms of SZYZ alone or in combination with oseltamivir. RESULTS: In healthy humans, SZYZ profoundly increased the total T cells, B cells, CD4+ T cells, and CD8+ T cells. 16S rRNA sequencing showed decreased airway microbes' diversity, enrichment of the genera Bacteroides and Bifidobacterium, and lowered phyla Actinobacteria, Synergistetes, and several opportunistic pathogens, including Actinomyces, Fretibacterium, Mobiluncus, and Cloacibacillus, and inhibited microbe functions of human disease and bacterial infectious pathways, after administration. Serum and fecal metabonomic identified changes in 138 and 197 metabolites, respectively. Airway Actinobacteria were negatively corelated to total T cells and CD8+T cells count. Serum methyl hexadecanoic acid levels were negatively correlated with T cell counts and positively with Actinobacteria abundance. In IAV-infected mice, SZYZ, administered either as a prophylactic intervention or in combination with oseltamivir, significantly reduced mortality and pathological damage, which were related to immunomodulatory mechanisms of oxidative stress, inflammatory cytokines, and lymphocyte ratio. CONCLUSION: We comprehensively elucidate the immunomodulatory effects of SZYZ's on microbiota, metabolism, and lymphocyte subpopulations, which provides a new therapeutic approach for the prevention and treatment of RTIs.
引用
- Wang Y, Wang X, Xu X, et al. Sang Zhu Yang Zheng herbal tea: A multi-faceted approach to immunomodulation in the prevention and treatment of respiratory tract infectious diseases. J Ethnopharmacol. 2025. PMID: 40609813. doi:10.1016/j.jep.2025.120229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。